Articles de revues : « Bendamustin »

1

Schmale, Ine. « Langzeitergebnisse mit Bendamustin ». Info Onkologie 19, n^o 1 (février 2016) : 60. http://dx.doi.org/10.1007/s15004-016-5242-y.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

red. « Neues Bendamustin-Generikum ». Info Onkologie 19, n^o 3 (avril 2016) : 50. http://dx.doi.org/10.1007/s15004-016-5315-y.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Berge, Doris. « Dreierkombination mit Bendamustin ». Info Onkologie 15, n^o 8 (décembre 2012) : 50. http://dx.doi.org/10.1007/s15004-012-0471-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

red. « Neues Bendamustin-Generikum ». Im Focus Onkologie 19, n^o 3 (mars 2016) : 69. http://dx.doi.org/10.1007/s15015-016-2434-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

red. « Bendamustin in neuer Packung ». Info Onkologie 18, n^o 3 (avril 2015) : 50. http://dx.doi.org/10.1007/s15004-015-0837-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

ul. « Bendamustin in der Primärtherapie ». best practice onkologie 8, n^o 1 (février 2013) : 31. http://dx.doi.org/10.1007/s11654-013-0031-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Reich, Bettina. « Multiples Myelom : Bendamustin als effektiver Partner für moderne Therapieregime ». Onkologische Welt 03, n^o 06 (2012) : 259. http://dx.doi.org/10.1055/s-0038-1630274.

Texte intégral

Résumé :

Bendamustin hat sich als Basismedikament zur Behandlung von niedrig malignen Lymphomen etabliert. Registerdaten aus dem hämato-onkologischen Alltag zeigen, dass Bendamustin heute in der Praxis bei indolenten Lymphomen und der chronischen lymphatischen Leukämie als häufigstes Zytostatikum eingesetzt wird (1).

Styles APA, Harvard, Vancouver, ISO, etc.

8

Werner, Walter, Michael Herold, Klaus Ruffert, Karlheinz Merkle, Axel Brakhage, Lorenzo Leoni et Bruce D. Cheson. « Entwicklungsgeschichte : Bendamustin gestern, heute, morgen ». Onkologie 36, s1 (2013) : 2–10. http://dx.doi.org/10.1159/000346104.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Arnheim, Katharina. « CLL : Ibrutinib schlägt Bendamustin/Rituximab ». InFo Hämatologie + Onkologie 22, n^o 1-2 (février 2019) : 51. http://dx.doi.org/10.1007/s15004-019-6397-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

arn. « Bendamustin-Regime auf dem Prüfstand ». Info Onkologie 15, n^o 3 (avril 2012) : 50. http://dx.doi.org/10.1007/s15004-012-5049-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

red. « Bendamustin/Rituximab verträglich bei CLL ». Info Onkologie 17, n^o 2 (mars 2014) : 53. http://dx.doi.org/10.1007/s15004-014-0788-z.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

von Kieseritzky, Kathrin. « CLL : Bendamustin-Rituximab weniger toxisch ? » Im Focus Onkologie 19, n^o 11 (novembre 2016) : 24. http://dx.doi.org/10.1007/s15015-016-2930-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Semenova, A. A., A. V. Arakelyan, P. A. Zeynalova, G. S. Tumyan, V. B. Larionova, T. T. Valiev, F. M. Abbasbeyli, O. L. Timofeeva, A. S. Antipova et O. A. Lopuhova. « Experience with the use of bendamustine (Rozustin®) : safety and efficacy ». Oncohematology 15, n^o 3 (16 octobre 2020) : 27–37. http://dx.doi.org/10.17650/1818-8346-2020-15-3-27-37.

Texte intégral

Résumé :

Background. Bendamustine is one of the main drugs included in the arsenal of cytostatic agents that are used in oncohematology. In Russia, the drug was registered at the end of 2010 under the commercial name Ribomustin (company Astellas). At the end of 2018, two national generics of bendamustine appeared on the Russian market – Rozustin® (Rafarma) and Kovada (Biocad).Materials and methods. In 2019 the department of hemoblastosis chemotherapy of the N. N. Blokhin National Medical Research Center of Oncology received the drug bendamustin (Rozustin®) (Rafarma, Russia). This article presents the first experience of using Rozustin® in patients with various lymphoproliferative diseases. Most often, the drug was used for relapsed or refractory classical Hodgkin’s lymphoma.Results and conclusion. The high effectiveness, acceptable toxicity profile compared to alternative “salvage” regimens, ease of implementation, and the possibility of a full collection of hematopoietic stem cells followed by high-dose chemotherapy and autologous stem cell transplant, confirm the good potential of the combined program with the inclusion of the drug bendamustine (Rozustin®).

Styles APA, Harvard, Vancouver, ISO, etc.

14

Arnheim, Katharina. « Praxis bestätigt Studienergebnisse : Bendamustin – Eckpfeiler in der Therapie der CLL ». Onkologische Welt 02, n^o 06 (2011) : 269. http://dx.doi.org/10.1055/s-0038-1632114.

Texte intégral

Résumé :

Die Therapieoptionen bei der chronischen lymphatischen Leukämie (CLL) haben sich erheblich erweitert. Ein großer Fortschritt war die Entwicklung der Immunchemotherapie unter Einschluss von Rituximab. Jetzt geht es darum, diesen Ansatz weiter zu optimieren. Als Eckpfeiler der Therapie bietet sich Bendamustin an, das aufgrund seiner hohen Effektivität und guten Verträglichkeit ein günstiges Nutzen/Risiko-Profil besitzt. Das belegt u. a. eine Phase-III-Studie, in der CLL-Patienten stärker von Bendamustin als von Chlorambucil profitierten.

Styles APA, Harvard, Vancouver, ISO, etc.

15

Neumaier, Judith. « Bendamustin plus Rituximab erfolgreich bei CLL ». Im Focus Onkologie 15, n^o 11 (novembre 2012) : 20. http://dx.doi.org/10.1007/s15015-012-0536-x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Leiner, Peter, et Wolfgang Abenhardt. « Bendamustin plus Rituximab für NHL-Patienten ». Im Focus Onkologie 16, n^o 6 (juin 2013) : 20. http://dx.doi.org/10.1007/s15015-013-0480-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Eiβfeller, Petra. « Fallkonferenz auf dem DGHO : Therapieerfahrungen mit Bendamustin ». Onkologische Welt 01, n^o 06 (2010) : 251. http://dx.doi.org/10.1055/s-0038-1631087.

Texte intégral

Résumé :

Die Hämatoonkologie profitiert nicht nur durch neue, zielgerichtete” Therapien. Mit Bendamustin (Ribomustin®) hat sich eine in Deutschland lange etablierte Substanz jetzt auch international in Therapieregimen bei zahlreichen Lymphom-Entitäten durchgesetzt. Auf dem der DGHO-Herbsttagung diskutierten Experten über ihre Erfahrungen anhand von Fallbeispielen.

Styles APA, Harvard, Vancouver, ISO, etc.

18

Pommer, P. « Bendamustin bei niedrig malignem Non-Hodgkin-Lymphom ? » DMW - Deutsche Medizinische Wochenschrift 138, n^o 25/26 (12 juin 2013) : 1339. http://dx.doi.org/10.1055/s-0033-1338050.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Heß, Georg. « Bendamustin plus Rituximab als Erstlinienbehandlung indolenter Lymphome ». Info Onkologie 16, n^o 4 (mai 2013) : 17–18. http://dx.doi.org/10.1007/s15004-013-0139-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Berger, Doris. « Bendamustin plus Rituximab — wirksam und gut verträglich ». Info Onkologie 17, n^o 7 (novembre 2014) : 63. http://dx.doi.org/10.1007/s15004-014-1003-y.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

db. « Bendamustin plus Rituximab — wirksam und gut verträglich ». best practice onkologie 9, n^o 6 (décembre 2014) : 32. http://dx.doi.org/10.1007/s11654-014-0566-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Berger, Doris. « Bendamustin/Rituximab bei älteren, fitten CLL-Patienten ». Im Focus Onkologie 18, n^o 1-2 (février 2015) : 69–70. http://dx.doi.org/10.1007/s15015-015-1622-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Kreutzkamp, Barbara. « NHL und Mantelzelllymphom : Vorteile für Bendamustin/Rituximab ». Im Focus Onkologie 19, n^o 7-8 (juillet 2016) : 26. http://dx.doi.org/10.1007/s15015-016-2686-8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Arnheim, Katharina. « Bendamustin beim multiplen Myelom : Auch Patienten mit ungünstiger Zytogenetik sprechen an ». Onkologische Welt 03, n^o 01 (2012) : 24. http://dx.doi.org/10.1055/s-0038-1631016.

Texte intégral

Résumé :

In der Therapie indolenter Lymophome und der chronisch lymphatischen Leukämie hat Bendamustin heute einen festen Platz. Jetzt werden auch beim multiplen Myelom vielversprechende Ergebnisse mit der Substanz berichtet.

Styles APA, Harvard, Vancouver, ISO, etc.

25

Graß, Sabrina. « Bendamustin gilt als Basistherapeutikum für Patienten mit CLL ». Im Focus Onkologie 15, n^o 6 (juin 2012) : 81. http://dx.doi.org/10.1007/s15015-012-0320-y.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

red. « First-Line-Therapie mit Bendamustin bei fortgeschrittener CLL ». Im Focus Onkologie 16, n^o 1-2 (février 2013) : 73. http://dx.doi.org/10.1007/s15015-013-0061-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

red. « CLL : Bendamustin für fitte Patienten über 65 Jahren ». Info Onkologie 18, n^o 6 (octobre 2015) : 65. http://dx.doi.org/10.1007/s15004-015-0972-9.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Kircali, Ekin, Guldane Cengiz, Sevgi Çolak, Mehmet Gunduz, Pinar Ataca Atilla, Erden Atilla, Mehmet Özen, Muhit Ozcan et Meral Beksac. « Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma : Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent ». Blood 136, Supplement 1 (5 novembre 2020) : 13–14. http://dx.doi.org/10.1182/blood-2020-137486.

Texte intégral

Résumé :

Introduction: Bendamustine is a synthetic alkylating agent made of both mustard and benzimidazole groups. It is used mainly in myeloma patients who have run out of classical treatment options and yet, have eligible performance status. Although data is still accumulating, there is not enough information to recommend a certain standard bendamustine dose or regimen in multiple myeloma. Melflufen is also an alkylator that is activated once metabolized by peptidases [1]. The logic this molecule selects and exterminates myeloma tumor cells by is that, myeloma cells overexpress aminopeptidases. Here, we have compared our and published bendamustine combination with melfufen data. Methods: We retrospectively analyzed our relapsed or refractory multiple myeloma patients who received bendamustine between 2002 and 2020 at Ankara University Medical School. All statistical analyses were performed via SPSS statistics version 20.0 software. After Pubmed search, all published bendamustine combination and melflufen clinical data among relapse refractory myeloma patients were included in the analysis. Results: Female/ male ratio was 14/ 18 (43.7 % / 56.3 %). Median age was 62 (36- 77) years. 22 (68.7 %) patients had Ig G myeloma, 6 (18.7 %) had Ig A myeloma and 4 (12.6 %) had light chain myeloma. ISS scores were as follows: I/ II/ III: 8 (25 %)/ 17 (53.1 %)/ 7 (21.9 %). FISH defined cytogenetics were available for 18 patients; 8 of them had normal chromosome analysis, 3 had only del13q, 1 had tri7. High risk cytogenetics was observed among 6 (33.3 %). R-ISS scores were as follows: I/ II/ III: 4 (22.2 %)/ 12 (66.7 %)/ 2 (11.1 %). Median prior lines of therapy was 3 (1- 6). 30 (93.8 %) patients had a history of bortezomib, 21 (65.6 %) had lenalidomide, 9 (28.1 %) had thalidomide. 21 (65.6 %) patients had undergone high-dose chemotherapy supported by autologous stem cell transplantation before bendamustine. 15 (46.9 %) patients were in treatment- refractory status at bendamustin initiation while 17 (53.1 %) used it for disease progression. Bendamustin was given either with Dexa (n= 13, 40.6 %) Bortezomib+ Dexa (n=6, 18.8 %), Lenalidomide+ Dexa (n=6, 18.8 %), Pomalidomide+ Dexa (n=5, 15.6 %) or Thalidomide+ Dexa (n= 2, 6.3 %). Bendamustine dose was 100- 120 mg/ m2/ day, 2 days monthly. 32 patients were followed up for median 26 months. Response to bendamustine treatment were as follows: Complete remission 4 (12.5 %), very good partial response 12 (37.5 %), partial response 8 (25 %), unresponsive 8 (25 %). Median progression free survival (PFS) was 5.6 (1- 40.6) months and overall survival (OS) was 17.3 (2- 79) months with bendamustine based treatment protocols. 15 (46.9 %) patients suffered grade ≥3 myelosuppression. Febrile neutropenia was experienced by 7 (21.9 %) patients, and 6 (18.7 %) had CMV reactivation during bendamustine treatment. There was no drug related mortality. Conclusion: Although bendamustine is effective among highly refractory myeloma patients, toxicity profile and immune plus myelosuppression prevents long term use. Bendamustine in our experience in combination has provided efficacy comparable to earlier publications. Current single agent Melflufen data in advanced stages may be even more promising if combined with proteasome inhibitors or IMIDs. References 1. Richardson, P.G., et al., Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. The Lancet Haematology, 2020. 2. Knop, S., et al., The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. haematologica, 2005. 90(9): p. 1287-1288. 3. Grey-Davies, E., et al., Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. British journal of haematology, 2012. 156(4): p. 552-555. 4. Damaj, G., et al., Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leukemia & lymphoma, 2012. 53(4): p. 632-634. 5. Ludwig, H., et al., Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood, The Journal of the American Society of Hematology, 2014. 123(7): p. 985-991. Disclosures Ozcan: Abdi Ibrahim: Other; Archigen Biotech: Research Funding; Amgen: Honoraria, Other: Travel support; Bristol Myers Squibb: Other: Travel support; Jazz Pharmaceuticals: Other; Sanofi: Other; F. Hoffmann-La Roche Ltd: Other: Travel support, Research Funding; Celgene: Research Funding; MSD: Research Funding; Janssen: Other: Travel support, Research Funding; AbbVie: Other: Travel support, Research Funding; Bayer: Research Funding; Takeda: Honoraria, Other: Travel support, Research Funding.

Styles APA, Harvard, Vancouver, ISO, etc.

29

Arnheim, Katharina. « Offene Fragen in der CLL-Therapie : Was ist das optimale Regime für den älteren Patienten ? » Onkologische Welt 03, n^o 02 (2012) : 86. http://dx.doi.org/10.1055/s-0038-1631023.

Texte intégral

Résumé :

Patienten mit chronischer lymphatischer Leukämie (CLL) sind meist bereits bei Diagnose in höherem Alter und haben daher oft Begleiterkrankungen. Die intensive Immunchemotherapie mit Fludarabin, Cyclophosphamid und Rituximab (FCR) kommt für sie nicht infrage. Hier könnten Bendamustin-Regime eine interessante Alternative sein.

Styles APA, Harvard, Vancouver, ISO, etc.

30

Schmidt, P., H. K. Heck et J. Preiss. « Bendamustin/mitoxantrone in the treatment of advanced breast cancer ». European Journal of Cancer 35 (septembre 1999) : S324. http://dx.doi.org/10.1016/s0959-8049(99)81717-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Reisdorf, Simone. « Lymphom-Register : Auch CLL-Patienten häufig mit Bendamustin behandelt ». Onkologische Welt 03, n^o 06 (2012) : 265. http://dx.doi.org/10.1055/s-0038-1630267.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Goldschmidt, Hartmut, Martin Kropff, Lars-Olof Mügge et Wolfram Pönisch. « Therapiestrategien beim Multiplen Myelom : die künftige Rolle von Bendamustin ». Onkologie 36, s1 (2013) : 19–26. http://dx.doi.org/10.1159/000346107.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Krome, Susanne. « Chronisch lymphatische Leukämie ». Onkologische Welt 10, n^o 03 (juillet 2019) : 126. http://dx.doi.org/10.1055/a-0870-8306.

Texte intégral

Résumé :

Bei Patienten mit rezidivierter und refraktärer chronisch lymphatischer Leukämie (CLL) verlängerte der Bruton-Tyrosinkinase-Inhibitor Ibrutinib das progressionsfreie Überleben (PFS) und ist seit 2016 auch als Erstlinienbehandlung zugelassen. Die Phase-III-Studie verglich 3 Therapieprotokolle für unbehandelte CLL-Patienten ≥ 65 Jahre: Bendamustin plus Rituximab, Ibrutinib sowie Ibrutinib plus Rituximab.

Styles APA, Harvard, Vancouver, ISO, etc.

34

Arnheim, Katharina. « Folgetherapien werden verzögert ». Onkologische Welt 08, n^o 05 (septembre 2017) : 235. http://dx.doi.org/10.1055/s-0038-1639643.

Texte intégral

Résumé :

Beim Non-Hodgkin-Lymphom (NHL) hat sich die Erstlinientherapie mit Bendamustin/ Rituximab (BR) als langfristig effektiv und sicher erwiesen: Im Vergleich zum Regime CHOP-Rituximab (CHOP-R) wird das Intervall bis zur nächsten Therapie erheblich verlängert; die 10-Jahres-Überlebensrate liegt bei 70 %, berichtete Prof. Dr. Mathias Rummel, Gießen, auf dem diesjährigen ASCO.

Styles APA, Harvard, Vancouver, ISO, etc.

35

Gulden, Josef. « Indolente NHL : Wirksamkeit von Bendamustin First-Line in Praxis bestätigt ». Info Onkologie 17, n^o 1 (février 2014) : 44. http://dx.doi.org/10.1007/s15004-014-0719-z.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Rahn, Angelika N., R. Burkhart Schilcher, Irenäus A. Adamietz, Stephan Mose, Sabine B. Bormeth et Heinz D. Böttcher. « Palliative Radiochemotherapie mit Bendamustin bei fortgeschrittenen Tumorrezidiven im HNO-Bereich ». Strahlentherapie und Onkologie 177, n^o 4 (mars 2001) : 189–94. http://dx.doi.org/10.1007/pl00002397.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Hrusovsky, Irena, et Hans-Heinrich Heidtmann. « Combination Therapy of Bortezomib with Bendamustin in Elderly Patients with Advanced Multiple Myeloma. Clinical Observation. » Blood 110, n^o 11 (16 novembre 2007) : 4851. http://dx.doi.org/10.1182/blood.v110.11.4851.4851.

Texte intégral

Résumé :

Bortezomib(Bo) was approved for therapy of relapsed Multiple Myeloma (MM) in 2003-for use in Germany 2004. There is growing evidence that combination of Bo with conventional chemotharapy agents could improve MM patients’ (pts) outcome(P.Richardson ASCO 2004). Bendamustin(Ben) is widely used for MM chemotherapy in Germany. In weekly low dose regimen it is well tolerated and highly effective in therapy of low grade lymphoma in elderly (K.Bremer ASCO2003, Abstract 2410). Ben has no cross resistances with other cytostatic drugs used in MM therapy, in low dose regimen it is well tolerated, has low bone marrow toxicity and no renal toxicity. We reported results of the combination therapy of the first 17 pts 2 years ago. Because of very good tolerability and high response rates we established the combination in our institution as a salvage-therapy for pts with relapsed MM after at least 2 previous chemotherapies. Till now we treated 40 pts - all white European-21 women, 19 men- median age 66 years (range 51–86). All pts had relapsed MM with clinical symptoms such as anemia, bone pain, progressive bone disease, several of the pts had renal failure (1 on hemodialysis). Previous therapies - median 4-(range 2–10)- included Melphalan, Dexamethason, VAD and sim. combinations, Cyclophosphamide, Bendamustin, Thalidomide, Bortezomib mono and in 3 pts tandem HD Melphalan. Therapy-regimen: Bortezomib 1–1,3 m/sqm d 1,4,8,11, Bendamustin 60mg/sqm d 1,8, Dexamethason 3x8mmg p.o. d 1–3 and 8–10 if tolerated, Ondansetron 8 mg i.v. d 1,4,8,11- q3w until best response- median number of cycles 4 (range 2–6). Early responses with symptom relief at begin of second cycle were frequently observed. Results (outcome according to SWOG criteria): ORR 85%, very good PR 25%(normal electrophoresis, normal level of free light chains in serum and urine), PR 47,5%, MR 12,5%. Remission duration in pts with at least PR- 8 Months (range 2–26 months)-19 pts are still alive. Toxicity: comprised fatigue and mostly mild thrombocytopenia without bleeding, reversible within 1 week. 8 pts had neuropathy and required symptomatic therapy with Gabapentine- most of them pretreated with Thalidomide. 9 pts had herpes zoster before aciclovir 3x400 mg daily was administered as prophylactic therapy. Conclusion: The therapy with combination Bortezomib- Bendamustin is highly effective, safe and well tolerated. The therapy is feasible in out-patient setting. The response rates suggest that the drugs act at least additive. We think therefore that further studies are warranted.

Styles APA, Harvard, Vancouver, ISO, etc.

38

Reich, Bettina. « Indolente Lymphome : Höherer Patientennutzen in der First-line-Therapie ». Onkologische Welt 02, n^o 03 (2011) : 119. http://dx.doi.org/10.1055/s-0038-1631250.

Texte intégral

Résumé :

Lange galt bei indolenten Lymphomen (iNHL) als First-line Standard die Immunochemotherapie. Hier und bei Mantelzell-Lymphomen hat ein Paradigmenwechsel stattgefunden. Denn Bendamustin plus Rituximab (B-R) ist im direkten Vergleich in randomisierten Studien anderen Immunochemotherapien wie CHOP-R oder F-R in der Primärtherapie als auch im Rezidiv überlegen. Interessant ist, dass jüngere Patienten mindestens in gleichem Maße von B-R profitieren wie ältere.

Styles APA, Harvard, Vancouver, ISO, etc.

39

Heider, A., W. Köster, J. Grote-Kiehn, K. Bremer, H. Wilke et N. Niederle. « Bendamustin in untreated small cell lung cancer (SCLC) : Efficacy and toxicity ». European Journal of Cancer 35 (septembre 1999) : S254. http://dx.doi.org/10.1016/s0959-8049(99)81429-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

Hiller, Erhard. « Ibrutinib versus Bendamustin/Rituximab in der Behandlung älterer Patienten mit CLL ». InFo Hämatologie + Onkologie 22, n^o 4 (avril 2019) : 28–30. http://dx.doi.org/10.1007/s15004-019-6472-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Arnheim, Katharina. « Therapieoptionen für den älteren CLL-Patienten : Bendamustin-Regime auf dem Prüfstand ». Im Focus Onkologie 15, n^o 4 (avril 2012) : 73. http://dx.doi.org/10.1007/s15015-012-0171-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

Kretzschmar, Alexander. « B-R schlägt CHOP-R um Längen bei Lymphomen ». Onkologische Welt 01, n^o 01 (2010) : 22. http://dx.doi.org/10.1055/s-0038-1631622.

Texte intégral

Résumé :

Bei unvorbehandelten follikulären, indolenten und Mantelzell-Lymphomen ist die Kombination Bendamustin-Rituximab (B-R) als First-Line-Therapie signifikant effektiver und dabei besser verträglich als das konventionelle CHOP-R-Schema. Die von Priv.-Doz. Dr. Mathias Rummel, Gießen, vorgestellten finalen Ergebnisse zeigen ein um 20,1 Monate längeres medianes progressionsfreies Überleben unter B-R (54,9 Monate; R-CHOP: 34,8 Monate; p = 0,00012) und eine signifikant höhere Komplettremissionsrate (B-R: 39,6 %; R-CHOP: 30,0 %, p = 0,0262).

Styles APA, Harvard, Vancouver, ISO, etc.

43

Knauf, Wolfgang Ulrich, Wolfgang Abenhardt, Arnd Nusch, Renate Grugel et Norbert Marschner. « Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres ». Blood 120, n^o 21 (16 novembre 2012) : 3666. http://dx.doi.org/10.1182/blood.v120.21.3666.3666.

Texte intégral

Résumé :

Abstract Abstract 3666 Introduction With the FDA and EMA approval of Bendamustine a new treatment option has recently become available to patients (pts) with indolent (low-grade) non-Hodgkin lymphoma (iNHL). Clinical registries provide insight into real-life treatment of pts. They can help to answer the question whether patients may benefit from new research findings. Methods The clinical registry on lymphoid neoplasms (TLN Registry), conducted by iOMEDICO in collaboration with the Arbeitskreis Klinische Studien (AKS) and the Kompetenznetz Maligne Lymphome (KML), prospectively collects data on the treatment of pts with lymphoid B-cell neoplasms as administered in hematology outpatient centres in Germany. Pts are followed for 5 years. A broad set of data regarding patient and tumor characteristics, comorbidities, all systemic treatments, response rates, progression-free survival and overall survival are recorded. Since May 2009, 106 sites have actively recruited a total of 2579 pts. Results From the overall sample, 645 pts received systemic 1st-line treatment for indolent Non-Hodgkin lymphoma (iNHL). 53% of pts are male, mean age at time of primary diagnosis was 65 years (yrs) and at start of therapy 66 yrs. Tumor stage was 7% Stage I, 15% Stage II, 25% Stage III and 54% Stage IV. 61% of pts (n=387) were diagnosed with at least one comorbidity, mainly hypertension (33%) or diabetes (12%); the average Charlson Comorbity Index of 0.6 indicates that pts have few comorbities. Rituximab is part of the 1st-line treatment in 94% (n=606) of pts with iNHL. Bendamustine is part of the 1st-line treatment in 71% (n=455) of pts with iNHL. It is mostly applied in combination with Rituximab (BR, 66%, n=428). Further 2% (n=10) receive Bendamustin as monotherapy. Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (R-CHOP) as 1st-line treatment is applied in 16% (n=105) of pts with iNHL. Pts receiving BR or R-CHOP differ. Pts characteristics indicate that BR is applied preferably in elderly pts (mean 67.3 vs. 60.9 yrs). However, BR is the preferred treatment also in pts younger than 66 yrs (60% vs. 23%). The use of BR has increased from 62% in 2009 to 68% in 2011, whereas the rate of R-CHOP has decreased from 19% in 2009 to 15% in 2011. Of all pts with iNHL, 121 have received 2nd-line treatment. Rituximab is part of the 2nd-line treatment in 84% (n=102) of pts with iNHL. Bendamustine is part of the 2nd-line treatment in 68% (n=82) of pts with iNHL. It is mostly applied in combination with Rituximab (BR, 60%, n=72). Further 7% (n=9) receive Bendamustin as monotherapy. R-CHOP as 2nd-line treatment is applied in 7% (n=9) of pts with iNHL. Conclusion BR is the most frequently used systemic treatment for pts with iNHL in German hematology outpatient centres. The use of BR has continuously increased since 2009. In contrast, the use of R-CHOP has decreased. This indicates that in Germany R-CHOP can no longer be considered as “standard of care” for pts with iNHL. These data also show that results from clinical trials are quickly implemented into daily practice. The impact of BR on quality of life and survival remains to be of central interest in the future. Disclosures: Knauf: Mundipharma GmbH: Honoraria, Membership on an entity's Board of Directors or advisory committees.

Styles APA, Harvard, Vancouver, ISO, etc.

44

Mark, Michael, et Thomas Cerny. « Neuere Medikamente in der Lymphomtherapie – eine Übersicht ». Therapeutische Umschau 67, n^o 10 (1 octobre 2010) : 537–43. http://dx.doi.org/10.1024/0040-5930/a000090.

Texte intégral

Résumé :

In der Lymphomtherapie sind in den vergangenen Jahren neue Medikamente entwickelt worden. Der monoklonale anti-CD20 Antikörper Rituximab revolutionierte die Behandlung der B-Zell-Non-Hodgkin-Lymphome. Die Weiterentwicklung führte zur Bildung von Rituximab-Radioimmunokonjugaten sowie vollständig humanisierter Antikörper. Bendamustin sowie Proteasominhibitoren haben bei nachgewiesener Wirksamkeit bereits die Zulassung bei einzelnen Lymphomentitäten erhalten. Histon-Deacetylase-Inhibitoren, die Idiotyp-Vakzinierung und weitere Moleküle zeigen vielversprechende Resultate in der Lymphomforschung, sodass diese zur Zeit in klinischen Studien weiter geprüft werden.

Styles APA, Harvard, Vancouver, ISO, etc.

45

Wollina, Uwe, Nadine Schmidt, Jacqueline Schönlebe, Aleksandra Vojvodic, Gesina Hansel, André Koch et Torello Lotti. « Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin ». Open Access Macedonian Journal of Medical Sciences 7, n^o 18 (30 juin 2019) : 3006–8. http://dx.doi.org/10.3889/oamjms.2019.565.

Texte intégral

Résumé :

BACKGROUND: Cutaneous B-cell lymphomas represent about 25% of all cutaneous lymphomas. Peripheral diffuse large B-cell lymphoma of the leg type is the most aggressive subtype seen mainly in elderly patients. Treatment is not standardised. CASE REPORT: An 87-year-old female patient was presented in May 2018 because of the development of painless subcutaneous nodules on the legs since late 2017. On examination, we observed up to 5 cm large erythematous nodules on the legs and a smaller plaque in the left submammary fold. The histology of a skin demonstrated tumour infiltrate that was separated from the overlying epidermis by a grenz zone. It consisted of densely packed, blastoid lymphocytic cells with numerous, and some atypical mitoses. The cells were positive for CD20, CD79A and CD5. Almost 100% of the cells were labelled with Ki67. The diagnosis of a diffuse large B-cell lymphoma (PCLBCL-LT) of the leg was confirmed. Histologic analysis of a bone marrow biopsy demonstrated a hypercellular bone marrow without malignant lymphatic infiltrates. Diagnostic ultrasound of cervical nodes and computerised tomography (CT) scans (native and with contrast medium) of head, neck and trunk excluded an extracutaneous manifestation of the PCLBCL-LT. Treatment with rituximab plus bendamustibe was initiated, but tumour progress was noted after the second course. Suggested palliative therapy with radiation and rituximab was refused. The patient died 7 months after diagnosis. CONCLUSIONS: Although some trials suggested a beneficial effect of immuno-chemotherapy, the prognosis of (PCLBCL-LT) remains poor. Standardised treatment is missing due to the relative rarity of this malignancy.

Styles APA, Harvard, Vancouver, ISO, etc.

46

Heider, A., F. Steffens, J. Koch et N. Niederle. « Bendamustin — Relapse therapy in patients with low grade non Hodgkin's lymphoma (NHL) ». European Journal of Cancer 33 (septembre 1997) : S270. http://dx.doi.org/10.1016/s0959-8049(97)86129-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

Bicskó, Réka Ráhel, Ferenc Magyari, Árpád Illés et Lajos Gergely. « Diffúz nagy B-sejtes limfóma autológ transzplantációt követő relapszusának sikeres kezelése rituximab-bendamustinvenetoclax kombinációs kezeléssel ». Hematológia–Transzfuziológia 53, n^o 4 (12 décembre 2020) : 193–95. http://dx.doi.org/10.1556/2068.2020.53.4.4.

Texte intégral

Résumé :

Összefoglaló. Az autológ őssejt-transzplantáció után visszaeső diffúz nagy B-sejtes limfómás betegek kezelése nagy kihívást jelent. Az újabban alkalmazott kismolekulák, illetve a CAR-T-sejtes terápia ígéretes kezelési lehetőségek, de ezekkel még nincs megfelelő tapasztalat, illetve csak bizonyos betegcsoportban alkalmazhatók. A munkában egy autológ hemopoetikus őssejt-transzplantáció után visszaeső diffúz nagy B-sejtes limfómás beteg sikeres kezelését mutatják be a szerzők rituximab-bendamustin-venetoclax kombinációs indukciós terápiával, amit 1 éves fenntartó venetoclaxkezelés követett. A beteg a kezelést végig jól tolerálta, tartós remisszió alakult ki. Az eset jól példázza, hogy az új kismolekulák alkalmazása nemcsak az indukcióban, hanem fenntartó kezelésként is szóba jöhet egyes betegekben. Summary. Treatment of patients with relapse of diffuse large B-cell lymphoma after autologous stem cell transplantation is a major challenge. Recently used small molecules and CAR-T-cell therapy are promising treatment options, but are not always available, and can only be used in certain groups of patients. In this paper the authors demonstrate the successful treatment of a relapsed diffuse large B-cell lymphoma patient after autologous hematopoietic stem cell transplantation with rituximab-bendamustine-venetoclax induction therapy for 6 cycles, followed by 12 months venetoclax maintenance therapy. The patient tolerated the induction and maintenance well, a sustained complete remission was achieved. The case highlights the possible implication of the novel small molecules not only in induction but maintenance treatment as well.

Styles APA, Harvard, Vancouver, ISO, etc.

48

Tzachanis, Dimitrios, Ayad Hamdan, Erik J. Uhlmann et Robin M. Joyce. « Erfolgreiche Behandlung eines therapierefraktären Guillain-Barré-Syndroms mit Alemtuzumab bei einem Patienten mit chronischer lymphatischer Leukämie ». Kompass Onkologie 2, n^o 1 (2015) : 43–46. http://dx.doi.org/10.1159/000381371.

Texte intégral

Résumé :

Dies ist der Fall eines 79-jährigen Mannes mit chronischer lymphatischer Leukämie, der sich etwa 6 Monate nach einer Therapie mit Bendamustin und Rituximab mit einem Guillain-Barré-Syndrom vorstellte, dessen Merkmale sich mit denen des Miller-Fisher-Syndroms und der Bickerstaff-Hirnstammenzephalitis überschnitten. Zugleich lagen Antikörper gegen das Gangliosid GQ1b vor. Sein klinischer und neurologischer Zustand verschlechterte sich zusehends, obwohl er sequenziell mit Kortikosteroiden, intravenösem Immunglobulin und Plasmapherese behandelt wurde. Schließlich sprach er jedoch vollständig und dauerhaft auf eine Behandlung mit Alemtuzumab an.

Styles APA, Harvard, Vancouver, ISO, etc.

49

Knipp, S., A. Kuendgen, C. Strupp, M. Aivado, R. Haas, N. Gattermann et U. Germing. « P-107 Treatment of patients with high-risk MDS and sAML with Bendamustin ». Leukemia Research 29 (janvier 2005) : S64—S65. http://dx.doi.org/10.1016/s0145-2126(05)80171-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Knauf, Wolfgang Ulrich, Wolfgang Abenhardt, Arnd Nusch, Renate Grugel et Norbert Marschner. « Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres ». Blood 120, n^o 21 (16 novembre 2012) : 4605. http://dx.doi.org/10.1182/blood.v120.21.4605.4605.

Texte intégral

Résumé :

Abstract Abstract 4605 Introduction With the FDA and EMA approval of Bendamustine and Rituximab new treatment options have recently become available to patients (pts) with chronic lymphocytic leukemia (CLL). Clinical registries provide insight into real-life treatment of pts. They can help to answer the question whether patients may benefit from new research findings. Methods The clinical registry on lymphoid neoplasms (TLN Registry), conducted by iOMEDICO in collaboration with the Arbeitskreis Klinische Studien (AKS) and the Kompetenznetz Maligne Lymphome (KML), prospectively collects data on the treatment of pts with lymphoid B-cell neoplasms as administered in hematology outpatient centres in Germany. Pts are followed for 5 years. A broad set of data regarding patient and tumor characteristics, comorbidities, all systemic treatments, response rates, progression-free survival and overall survival are recorded. Since May 2009, 106 sites have actively recruited a total of 2579 pts. Results From the overall sample, 420 pts received systemic 1st-line treatment for CLL. 65% of pts are male, mean age at time of primary diagnosis was 66 years (yrs) and at start of therapy 69 yrs. Tumor stage was 20% Binet A, 35% Binet B and 45% Binet C. 68% of pts (n=285) were diagnosed with at least one comorbidity, mainly hypertension (37%) or diabetes (15%); the average Charlson Comorbity Index of 0.7 indicates that overall pts have few comorbities. Rituximab is part of the 1st-line treatment in 82% (n=345) of pts with CLL. Bendamustine is part of the 1st-line treatment in 59% (n=247) of pts with CLL. It is mostly applied in combination with Rituximab (BR, 51%, n=213). Further 7% (n=28) receive Bendamustin as monotherapy. Fludarabine is part of the 1st-line treatment in 31% (n=132) of pts with CLL. It is applied in combination with Cyclophosphamide and Rituximab (FCR, 25%, n=103), as monotherapy (4%, n=15) or in combination with Cyclophosphamide (FC, 1%, n=6). Chlorambucil is part of the 1st-line treatment in 7% (n=31) of pts with CLL. It is applied as monotherapy (4%, n=15) or in combination with Rituximab (2%, n=10). Pts receiving BR, FCR or Chlorambucil differ. Pts characteristics indicate that BR and Chlorambucil are applied preferably in elderly pts (mean 70.1 (BR) vs. 75.7 (Chlorambucil) vs. 63.4 (FCR) yrs). Also, BR is given preferably in advanced stages of the disease as compared to FCR (Binet C 49% vs. 34%). The use of BR has increased from 41% in 2009 to 57% in 2011, while the use of FCR has decreased from 33% in 2009 to 17% in 2011. Of all pts with CLL in the TLN, 181 have received 2nd-line treatment. Rituximab is part of the 2nd-line treatment in 76% (n=137) of pts with CLL. Bendamustine is part of the 2nd-line treatment in 66% (n=120) of pts with CLL. It is mostly applied in combination with Rituximab (BR, 56%, n=101). Further 10% (n=18) receive Bendamustin as monotherapy. Fludarabine is part of the 2nd-line treatment in 20% (n=37) of pts with CLL. It is applied in combination with Cyclophosphamide and Rituximab (FCR, 10%, n=18), as monotherapy (5%, n=9) or in combination with Cyclophosphamide (FC, 3%, n=5). Chlorambucil is part of the 2nd-line treatment in 4% (n=7) of pts with CLL. It is mostly applied in combination with Rituximab (2%, n=4). Conclusion Rituximab and Bendamustine are the most frequently used drugs for the treatment of CLL in German hematology outpatient centres. The use or BR has significantly increased since 2009. In contrast, the use of FCR has decreased and only a minority of pts receive Chlorambucil. This indicates that in Germany Chlorambucil is no longer considered the “standard of care” for elderly pts with CLL. These data also show that results from clinical trials are quickly implemented into daily practice. The impact of these new treatment options on quality of life and survival remains to be of central interest in the future. Disclosures: Knauf: Mundipharma GmbH: Honoraria, Membership on an entity's Board of Directors or advisory committees.

Styles APA, Harvard, Vancouver, ISO, etc.

Articles de revues sur le sujet « Bendamustin »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres